Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

• Published in: NeuroImage (Orlando, Fla.) Vol. 45; no. 4; pp. 1107 - 1116
• Main Authors: Langbaum, Jessica B.S., Chen, Kewei, Lee, Wendy, Reschke, Cole, Bandy, Dan, Fleisher, Adam S., Alexander, Gene E., Foster, Norman L., Weiner, Michael W., Koeppe, Robert A., Jagust, William J., Reiman, Eric M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2009; Elsevier Limited
• Subjects: Aged; Alzheimer Disease - diagnostic imaging; Alzheimer's disease; Cerebral Cortex - diagnostic imaging; Cognition Disorders - diagnostic imaging; Cognitive ability; Dementia; Female; Fluorodeoxyglucose F18; Humans; Male; MCI; Medical imaging; Middle Aged; MMSE; Positron emission tomography; Positron-Emission Tomography - methods; Radiopharmaceuticals; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Studies; MCI; Alzheimer's disease; Positron emission tomography; MMSE
• ISSN: 1053-8119; 1095-9572; 1095-9572
• DOI: 10.1016/j.neuroimage.2008.12.072

In mostly small single-center studies, Alzheimer's disease (AD) is associated with characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (CMRgl). The AD Neuroimaging Initiative (ADNI) is acquiring FDG PET, volumetric magnetic resonance imaging, and other biomarker measurements in a large longitudinal multi-center study of initially mildly affected probable AD (pAD) patients, amnestic mild cognitive impairment (aMCI) patients, who are at increased AD risk, and cognitively normal controls (NC), and we are responsible for analyzing the PET images using statistical parametric mapping (SPM). Here we compare baseline CMRgl measurements from 74 pAD patients and 142 aMCI patients to those from 82 NC, we correlate CMRgl with categorical and continuous measures of clinical disease severity, and we compare apolipoprotein E (APOE) ɛ4 carriers to non-carriers in each of these subject groups. In comparison with NC, the pAD and aMCI groups each had significantly lower CMRgl bilaterally in posterior cingulate, precuneus, parietotemporal and frontal cortex. Similar reductions were observed when categories of disease severity or lower Mini-Mental State Exam (MMSE) scores were correlated with lower CMRgl. However, when analyses were restricted to the pAD patients, lower MMSE scores were significantly correlated with lower left frontal and temporal CMRgl. These findings from a large, multi-site study support previous single-site findings, supports the characteristic pattern of baseline CMRgl reductions in AD and aMCI patients, as well as preferential anterior CMRgl reductions after the onset of AD dementia.